Ascendis Pharma A/S (ASND): Price and Financial Metrics

Ascendis Pharma A/S (ASND): $89.50

-5.89 (-6.17%)

POWR Rating

Component Grades













Add ASND to Watchlist
Sign Up

Industry: Biotech



in industry


  • ASND scores best on the Sentiment dimension, with a Sentiment rank ahead of 59.61% of US stocks.
  • ASND's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • ASND's current lowest rank is in the Quality metric (where it is better than 7.17% of US stocks).

ASND Stock Summary

  • Ascendis Pharma A's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.87% of US listed stocks.
  • With a price/sales ratio of 786.64, Ascendis Pharma A has a higher such ratio than 99.43% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.22 for Ascendis Pharma A; that's greater than it is for only 13.84% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Ascendis Pharma A, a group of peers worth examining would be CAPR, OTIC, VXRT, STRO, and LXRX.
  • ASND's SEC filings can be seen here. And to visit Ascendis Pharma A's official web site, go to

ASND Stock Price Chart Interactive Chart >

Price chart for ASND

ASND Price/Volume Stats

Current price $89.50 52-week high $178.71
Prev. close $95.39 52-week low $61.58
Day low $88.76 Volume 347,500
Day high $95.80 Avg. volume 454,579
50-day MA $88.94 Dividend yield N/A
200-day MA $121.33 Market Cap 5.10B

Ascendis Pharma A/S (ASND) Company Bio

Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.

ASND Latest News Stream

Event/Time News Detail
Loading, please wait...

ASND Latest Social Stream

Loading social stream, please wait...

View Full ASND Social Stream

Latest ASND News From Around the Web

Below are the latest news stories about Ascendis Pharma A that investors may wish to consider to help them evaluate ASND as an investment opportunity.

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its 2021 financial results and provide a business update. Conference Call Details DateWednesday, March 2, 2022Time4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeDial In (U.S.)844-290-3904Dial In (International)574-990-1036Access Code2009938 A live webcast of the co

Yahoo | February 25, 2022

Artisan Partners ‘Remains Quite Optimistic’ in Ascendis Pharma (ASND)

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of -0.72% was recorded by its Investor Class: ARTMX, -0.68% by its Advisor Class: APDMX, and -0.66% by its Institutional Class: APHMX, in the fourth […]

Yahoo | February 25, 2022

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will participate in a virtual fireside chat hosted by SVB Leerink.

GlobeNewswire | February 10, 2022

CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...

Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.

Yahoo | February 8, 2022

Read More 'ASND' Stories Here

ASND Price Returns

1-mo 5.06%
3-mo -21.68%
6-mo -23.41%
1-year -32.23%
3-year -20.36%
5-year 217.83%
YTD -33.47%
2021 -19.34%
2020 19.88%
2019 122.06%
2018 56.39%
2017 97.92%

Continue Researching ASND

Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:

Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8828 seconds.